Calming the Mind to Heal the Hip

Anxiety is increasingly recognized as an important determinant of recovery after total hip arthroplasty (THA). Patients who enter surgery with heightened anxiety tend to report worse pain and have inferior function and higher complication and readmission rates. In their randomized controlled trial, Jiang et al. directly address this problem by testing whether a simple, short-course pharmacologic intervention can meaningfully improve outcomes in this vulnerable group. Their findings are both intriguing and practically relevant for modern perioperative care. In this single-center trial, 135 patients undergoing primary THA who screened positive for substantial anxiety (State-Trait Anxiety Inventory-State [STAI-S], ≥40) were randomized to receive 1 of 3 nightly medications for a total of 5 days beginning at admission: low-dose oral olanzapine (2.5 mg), alprazolam (0.4 mg), or placebo. All patients were managed within an ERAS (Enhanced Recovery After Surgery) framework. The authors evaluated anxiety levels, sleep quality, pain, opioid consumption, postoperative nausea and vomiting, and functional outcomes. Several key results stand out. Compared with placebo, and even compared with alprazolam, olanzapine use was associated with significantly lower anxiety scores in the early postoperative period (postoperative days 1 and 3). Patients receiving olanzapine also reported less resting pain, consumed fewer opioids, slept better, and experienced less postoperative nausea and vomiting. Early functional recovery appeared modestly improved as well, reflected in higher patient-reported outcome metrics at a short-term follow-up. Importantly, adverse events were not significantly different among groups during the monitored period. Taken together, these findings reinforce something that every arthroplasty surgeon has observed in practice: the mind and body are not separate systems in recovery. Pain perception, sleep quality, and emotional state interact continuously, and intervening on 1 domain can beneficially influence others. In this sense, the study highlights anxiety not just as a risk factor but as a potentially modifiable therapeutic target. The choice of olanzapine is noteworthy. Although classically considered as an atypical antipsychotic, at low doses it has anxiolytic, antiemetic, and sedative-stabilizing properties, without the dependence concerns associated with benzodiazepines. The dose selected here (2.5 mg nightly) is far lower than typical psychiatric regimens, and the brief 5-day duration aligns well with perioperative workflows. Whether the benefits reflect anxiolysis, sleep stabilization, reduced perseveration regarding pain, or some combination of these mechanisms is less important clinically than the practical observation: patients with anxiety undergoing THA seemed to feel and function better. As with any single-center randomized controlled trial, the study had limitations. The follow-up window for adverse events was relatively short and the size was small, so rare or delayed effects could not be excluded. The trial was conducted in a Chinese inpatient population, and replication in other health-care environments, including in outpatient arthroplasty, will be important. Although the improvements in multiple outcomes were significant, surgeons must decide whether they are clinically meaningful enough to justify routine use. Nonetheless, the study advances a growing theme in arthroplasty: psychological readiness matters. Just as we optimize anemia, diabetes, nutrition, and smoking status, we may increasingly consider structured strategies for optimizing perioperative mental health. For some patients, that may mean counseling, education, reassurance, or non-pharmacologic approaches. For others, particularly those with measurable anxiety, a short, carefully monitored medication-based intervention may have a role. For practicing surgeons, several practical takeaways emerge. (1) Screen for anxiety. Many of us recognize it informally, but a simple validated tool may help to identify patients at risk. (2) Normalize the discussion. Patients benefit from hearing that anxiety is common and addressable. (3) Think beyond pain scores. Sleep, mood, and coping strongly influence recovery trajectories. Perhaps the most important reminder is that patients are not just surgical candidates; they are people experiencing uncertainty, vulnerability, and fear. Meeting them in that space may be as important as any technical achievement in the operating room. Jiang et al. have opened the door to a thoughtful discussion about pharmacologic anxiety management in arthroplasty. Future studies will help to determine where olanzapine, or similar agents, ultimately fits within routine practice. However, this trial moves the field forward by acknowledging something simple and human: calmer minds often heal hips better.